1 of 1
Story summary
- At ENDO 2026 researchers reported that adults with obesity who began GLP-1 receptor agonists cut their daily steps and moderate-to-vigorous activity.
- Using NIH All of Us data linked to Fitbit records, the study analyzed 1,950 participants, with 753 providing adequate wearable data.
- Average steps fell from 5,047 to 4,487 and activity minutes dropped from 28 to 22, with the sharpest declines in men and those reporting joint or muscle pain.
